<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114279">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615484</url>
  </required_header>
  <id_info>
    <org_study_id>UNC-002 Vitrolife</org_study_id>
    <secondary_id>1UM1HL113115-01A1</secondary_id>
    <nct_id>NCT01615484</nct_id>
  </id_info>
  <brief_title>Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability</brief_title>
  <official_title>Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vitrolife</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>XVIVO Perfusion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn about the safety of transplanting lungs
      obtained from non-heart-beating donors (NHBDs) that have been ventilated (attached to a
      breathing machine or ventilator to deliver oxygen) and perfused with a lung perfusion
      solution (Steen solution™, made by Vitrolife). This ventilation and perfusion will be done
      outside the body (ex-vivo) in a modified cardiopulmonary bypass circuit (the kind of device
      used routinely during most heart surgeries). The purpose of performing ex-vivo perfusion and
      ventilation is to learn how well the lungs work, and whether they are likely safe to
      transplant.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Funding suspended, currently seeking other funding source(s).
  </why_stopped>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>30 Day Mortality and Graft Survival</measure>
    <time_frame>30 Days</time_frame>
    <description>The primary objective evaluated for this study is recipient mortality and graft survival at 30 days post transplant. 30 day mortality and graft survival is used as a standard research assessment to evaluate post transplant outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Lung Graft Dysfunction (PGD)</measure>
    <time_frame>24 and 72 hours</time_frame>
    <description>Primary Lung Graft Dysfunction (PGD) is an indicator for significant morbidity and mortality after lung transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU Length of Stay</measure>
    <time_frame>Time to Discharge.</time_frame>
    <description>The length of ICU stay is another standard research and clinical outcome assessment post transplant and has been selected as a secondary objective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Day 7 Ventilator/ECMO Status</measure>
    <time_frame>7 Days Post Transplant.</time_frame>
    <description>7 days ventilator or extra-corporeal membrane oxygenator (ECMO) free are being evaluated as secondary objectives.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient mortality at 12 months.</measure>
    <time_frame>12 months</time_frame>
    <description>Recipient mortality at 12 months post transplant is being evaluated as a secondary objective.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchiolitis Obliterans Syndrome (BOS) free graft survival.</measure>
    <time_frame>12 Months</time_frame>
    <description>Bronchiolitis Obliterans Syndrome (BOS) free graft survival at 12 months is being used as a secondary outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Emphysema</condition>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <condition>Cystic Fibrosis</condition>
  <condition>Pulmonary Fibrosis</condition>
  <condition>Bronchiectasis</condition>
  <condition>Sarcoidosis</condition>
  <condition>Pulmonary Hypertension</condition>
  <condition>Alpha-1 Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>Ex-vivo lung perfusion with STEEN Solution™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The perfusion of the lungs will be performed using STEEN Solution™. The lungs will be physiologically assessed during ex vivo perfusion with STEEN Solution™ perfusate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung transplant from conventional brain-dead organ donor</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No experimental procedures will be carried out.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™</intervention_name>
    <description>After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.</description>
    <arm_group_label>Ex-vivo lung perfusion with STEEN Solution™</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STEEN Solution™</intervention_name>
    <description>This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.</description>
    <arm_group_label>Ex-vivo lung perfusion with STEEN Solution™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A recipient must meet the following requirement to enroll into the study:

          -  Requires a single or bilateral lung transplant and is listed for transplant at UNC or
             Duke

          -  Male or Female, 15 years of age or older.

          -  Subject or Subject's Representative provides a legally effective informed consent.

          -  Recipient does not have HIV, active Hepatitis or is colonized with Burkholderia
             cepacia.

          -  Potential subjects who have undergone previous lung transplants and meet all other
             inclusion criteria, are eligible for study participation.

        Exclusion Criteria:

        •Recipient fails to meet standard of care requirements for lung transplant, or decides not
        to participate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M. Egan, MD, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC-Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UNC-Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Orens JB, Estenne M, Arcasoy S, Conte JV, Corris P, Egan JJ, Egan T, Keshavjee S, Knoop C, Kotloff R, Martinez FJ, Nathan S, Palmer S, Patterson A, Singer L, Snell G, Studer S, Vachiery JL, Glanville AR; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation.. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2006 Jul;25(7):745-55.</citation>
    <PMID>16818116</PMID>
  </reference>
  <reference>
    <citation>Ingemansson R, Eyjolfsson A, Mared L, Pierre L, Algotsson L, Ekmehag B, Gustafsson R, Johnsson P, Koul B, Lindstedt S, Lührs C, Sjöberg T, Steen S. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg. 2009 Jan;87(1):255-60. doi: 10.1016/j.athoracsur.2008.09.049.</citation>
    <PMID>19101308</PMID>
  </reference>
  <reference>
    <citation>Mason DP, Thuita L, Alster JM, Murthy SC, Budev MM, Mehta AC, Pettersson GB, Blackstone EH. Should lung transplantation be performed using donation after cardiac death? The United States experience. J Thorac Cardiovasc Surg. 2008 Oct;136(4):1061-6. doi: 10.1016/j.jtcvs.2008.04.023.</citation>
    <PMID>18954650</PMID>
  </reference>
  <reference>
    <citation>Cypel M, Yeung JC, Hirayama S, Rubacha M, Fischer S, Anraku M, Sato M, Harwood S, Pierre A, Waddell TK, de Perrot M, Liu M, Keshavjee S. Technique for prolonged normothermic ex vivo lung perfusion. J Heart Lung Transplant. 2008 Dec;27(12):1319-25. doi: 10.1016/j.healun.2008.09.003.</citation>
    <PMID>19059112</PMID>
  </reference>
  <reference>
    <citation>Egan TM, Haithcock JA, Nicotra WA, Koukoulis G, Inokawa H, Sevala M, Molina PL, Funkhouser WK, Mattice BJ. Ex vivo evaluation of human lungs for transplant suitability. Ann Thorac Surg. 2006 Apr;81(4):1205-13.</citation>
    <PMID>16564244</PMID>
  </reference>
  <reference>
    <citation>Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D; ISHLT Working Group on Primary Lung Graft Dysfunction.. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2005 Oct;24(10):1454-9. Epub 2005 Jun 4.</citation>
    <PMID>16210116</PMID>
  </reference>
  <reference>
    <citation>Kim IK, Bedi DS, Denecke C, Ge X, Tullius SG. Impact of innate and adaptive immunity on rejection and tolerance. Transplantation. 2008 Oct 15;86(7):889-94. doi: 10.1097/TP.0b013e318186ac4a. Review.</citation>
    <PMID>18852649</PMID>
  </reference>
  <reference>
    <citation>Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, van Kasterop-Kutz M, van der Heide JJ, Squifflet JP, van Heurn E, Kirste GR, Rahmel A, Leuvenink HG, Paul A, Pirenne J, Ploeg RJ. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med. 2009 Jan 1;360(1):7-19. doi: 10.1056/NEJMoa0802289.</citation>
    <PMID>19118301</PMID>
  </reference>
  <reference>
    <citation>Cypel M, Liu M, Rubacha M, Yeung JC, Hirayama S, Anraku M, Sato M, Medin J, Davidson BL, de Perrot M, Waddell TK, Slutsky AS, Keshavjee S. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med. 2009 Oct 28;1(4):4ra9. doi: 10.1126/scitranslmed.3000266.</citation>
    <PMID>20368171</PMID>
  </reference>
  <reference>
    <citation>Cypel M, Yeung JC, Liu M, Anraku M, Chen F, Karolak W, Sato M, Laratta J, Azad S, Madonik M, Chow CW, Chaparro C, Hutcheon M, Singer LG, Slutsky AS, Yasufuku K, de Perrot M, Pierre AF, Waddell TK, Keshavjee S. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011 Apr 14;364(15):1431-40. doi: 10.1056/NEJMoa1014597.</citation>
    <PMID>21488765</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 8, 2016</lastchanged_date>
  <firstreceived_date>June 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of North Carolina, Chapel Hill</investigator_affiliation>
    <investigator_full_name>Tom Egan, MD,MsC</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>Lung Transplant</keyword>
  <keyword>Emphysema</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Pulmonary Fibrosis</keyword>
  <keyword>Bronchiectasis</keyword>
  <keyword>Sarcoidosis</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Alpha-1 Antitrypsin Deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual clinical outcome data will be made available upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
